Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

1997 • 897 citations

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 • 877 citations

Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study

1999 • 596 citations

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

1999 • 458 citations

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

1999 • 415 citations

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

1993 • 284 citations

Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases

1995 • 229 citations

Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in Adult Acute Myeloid Leukemia Patients

1998 • 208 citations

Novel mechanisms of drug resistance in leukemia

2000 • 205 citations

Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia

1999 • 181 citations

P-glycoprotein plays a drug-efflux–independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway

2000 • 157 citations

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score

2000 • 152 citations

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

1999 • 152 citations

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines

2000 • 148 citations

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

1999 • 122 citations

Measurement of Spontaneous and Therapeutic Agent-Induced Apoptosis With BCL-2 Protein Expression in Acute Myeloid Leukemia

1997 • 112 citations

The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.

1997 • 85 citations

Mechanisms of drug resistance in hematologic malignancies.

1997 • 64 citations

Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.

1994 • 59 citations

Drug resistance factors in acute myeloid leukemia: a comparative analysis

2000 • 59 citations

IN VITRO RESISTANCE TO CYTOSINE ARABINOSIDE, NOT TO DAUNORUBICIN, IS ASSOCIATED WITH THE RISK OF RELAPSE IN DE NOVO ACUTE MYELOID LEUKAEMIA

1996 • 57 citations

Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia

2000 • 48 citations

P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy

2000 • 46 citations

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

1999 • 42 citations

Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

1999 • 39 citations

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia

1999 • 36 citations

P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.

1998 • 35 citations

Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment

2000 • 33 citations

Binding and endocytosis of a monoclonal antibody to a high molecular weight human milk fat globule membrane-associated antigen by cultured MCF-7 breast carcinoma cells.

1988 • 28 citations

Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors.

1995 • 10 citations

Comparison of P-Glycoprotein Expression and Function with in vitro Sensitivity to Anthracyclines in AML

1999 • 8 citations

Intraclonal Heterogeneity in theIn VitroDaunorubicin-Induced Apoptosis in Acute Myeloid Leukemia

1999 • 6 citations

Cited By (0)

Loading...